Skin care composition and application thereof

Abstract

The invention relates to a skin care composition and application thereof, and belongs to the technical field of cosmetics. The invention provides a skin care composition which comprises ginsenoside RG2 and III-type collagen, the composition can effectively inhibit secretion of metal matrix protease MMP1 and remarkably increase gene expression of the III-type collagen and has a synergistic anti-wrinkle effect, and the ginsenoside RG2 and the III-type collagen used for preparing cosmetics are high in price, so that the skin care composition has a good anti-wrinkle effect. In this way, the usage amount of ginsenoside RG2 and III type collagen can be reduced, and the ginsenoside RG2 and III type collagen can exert equivalent functions under the condition of low usage amount, so that the cost is saved, and meanwhile, a better anti-wrinkle effect can be achieved.

Description

Technical Field

[0001] The present application relates to a skin care composition and application thereof, belonging to the technical field of cosmetics. Background Art

[0002] As we age, our skin is exposed to external factors such as prolonged exposure to the sun or ultraviolet radiation, microbial invasion, chemical substances, physical damage, etc., and the skin will gradually begin to age, and collagen loss will become faster and faster, especially after the age of 25. The synthesis rate of type I and III collagen in the skin cannot keep up with the loss rate, which will cause the skin to show wrinkles, sagging and other aging phenomena.

[0003] In the process of cosmetic preparation, some expensive materials are often needed. These raw materials play a key role in skin care and repair. However, due to their price factors, simply increasing the amount of these key active raw materials will lead to a significant increase in costs. In order to reduce the cost of cosmetic production, it is necessary to develop a combination of active ingredients with synergistic effects. This can greatly reduce the use of expensive active ingredients, so that these active ingredients can also exert their effects at low dosages, thereby achieving cost savings while achieving better skin care effects. Summary of the invention

[0004] In order to solve the above problems, a skin care composition is provided, comprising ginsenoside RG2 and type III collagen. The composition can effectively inhibit the secretion of matrix metalloproteinase MMP1, and can significantly increase the expression of type III collagen gene in fibroblasts, and has the effect of synergistically alleviating aging, thereby reducing the usage of ginsenoside and type III collagen, saving costs and achieving better alleviating aging effects.

[0005] According to a first aspect of the present application, a skin care composition is provided, comprising ginsenoside RG2 and type III collagen.

[0006] The skin care composition may be a skin anti-wrinkle composition, a skin external composition, an anti-aging composition, or a composition for promoting collagen production.

[0007] In some specific embodiments, the weight ratio of the ginsenoside RG2 to the type III collagen is 1 to 50:1.

[0008] Optionally, the weight ratio of the ginsenoside RG2 to the type III collagen is X:1, and X can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45, or 50.

[0009] Optionally, the weight ratio of the ginsenoside RG2 to the type III collagen is 1 to 30:1.

[0010] Optionally, the weight ratio of the ginsenoside RG2 to the type III collagen is 2 to 20:1.

[0011] In some specific embodiments, the concentration of ginsenosides ranges from 0.0001% to 1%.

[0012] In some specific embodiments, the concentration of type III collagen ranges from 0.0001% to 1%.

[0013] Optionally, the concentration of the ginsenoside can be 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.0 0.07%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, or any value or range therebetween;

[0014] Optionally, the concentration of type III collagen can be 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0. 0.07%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, or any value or range therebetween.

[0015] In some specific embodiments, the type III collagen comprises recombinant type III collagen.

[0016] In some specific embodiments, the molecular weight of the type III collagen is 1-10wDa. For example, the molecular weight of the type III collagen can be 1wDa, 1.5wDa, 2wDa, 2.5wDa, 3wDa, 3.5wDa, 4wDa, 4.5wDa, 5wDa, 5.5wDa, 6wDa, 6.5wDa, 7wDa, 7.5wDa, 8wDa, 8.5wDa, 9wDa, 9.5wDa, 10wDa, or any value or range therebetween.

[0017] In some specific embodiments, the type III collagen can be purchased or prepared by oneself.

[0018] In some specific embodiments, the type III collagen can be prepared by the method described in patent CN202210739807.1.

[0019] In some specific embodiments, the type III collagen may be the type III collagen described in patent CN202210739807.1.

[0020] In some specific embodiments, the composition further comprises physiologically acceptable excipients or other active ingredients.

[0021] Optionally, the excipients may be appropriate solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrators, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculating agents, filter aids, release retardants, etc.

[0022] It should be noted that the composition of the present application can be prepared by a general method, wherein one or more diluents or carriers can be added, such as capsules, suspensions, ointments, emulsions, aqueous solutions, etc.

[0023] According to the second aspect of the present application, there is provided a use of any of the above compositions.

[0024] In some embodiments, the composition described in the present application is used in the preparation of skin care products.

[0025] In some embodiments, the composition described in the present application is used to inhibit collagen degradation and / or promote collagen production.

[0026] In some embodiments, the promoting collagen production includes promoting type III collagen production.

[0027] In some embodiments, the compositions described herein are used as inhibitors of matrix metalloproteinase-1 (MMP-1) expression.

[0028] In some embodiments, the composition described in the present application is used as a promoter for promoting the expression of type III collagen (Collagen III).

[0029] In some embodiments, the composition described herein is used in preventing and / or alleviating aging.

[0030] Optionally, the prevention and / or alleviation of aging includes removing wrinkles and / or increasing skin elasticity.

[0031] In some embodiments, the composition described in the present application is used in the preparation of a skin external product.

[0032] Furthermore, the skin external product includes one or more of skin care products, makeup products, hair products, sunscreen products, and skin external medicines.

[0033] The beneficial effects of this application include but are not limited to:

[0034] The present application compounds ginsenoside RG2 and type III collagen according to the weight ratio provided by the present invention, and produces a synergistic effect on the inhibition rate of MMP1 secretion and the expression of type III collagen gene, thereby effectively inhibiting the degradation of collagen and promoting the production of endogenous type III collagen, thereby achieving a better effect of preventing and / or alleviating aging;

[0035] Furthermore, although the present application is not limited to the use of low concentrations of ginsenoside RG2 and type III collagen, through the above findings of the present application, the skin care composition of the present application can also exert good anti-aging effects while reducing the usage of ginsenoside RG2 and type III collagen, which provides a feasible path for cost saving. DETAILED DESCRIPTION

[0036] The present application is described in detail below in conjunction with the examples, but the present application is not limited to these examples. Unless otherwise specified, the raw materials and catalysts in the examples of the present application are purchased through commercial channels. Among them, recombinant type III collagen was purchased from Huaxi Biotechnology Co., Ltd., ginsenoside RG2 was purchased from Sanyi Technology (Guangzhou) Co., Ltd., and ginsenoside Rh1 was purchased from Sigma-Aldrich (Shanghai) Trading Co., Ltd.

[0037] The experimental method in this application includes the following steps:

[0038] 1) Test system: The cells used in this test are fibroblasts, provided by Guangdong Boxi Biotechnology Co., Ltd.;

[0039] 2) Main reagents: DMEM culture medium (Gibco), PBS (Solebio), MTT (Sigma), Collagen I ELISA kit (Cusabio);

[0040] 3) Main equipment: CO 2 Incubator (Thermo, 150I), clean bench (Sujing Antai, SW-CJ-1F), microplate reader (BioTek, Epoch), UVA irradiator (Philips);

[0041] 4) The test method includes the following steps:

[0042] 4.1) Cell seeding: After the cells are revived, when the plating rate reaches about 60%, the cells are seeded into 6-well plates and incubated in an incubator (37°C, 5% CO 2 ) and incubated overnight;

[0043] 4.2) Prepare samples according to the concentrations in Table 1 below. All samples are dissolved in DMEM culture medium;

[0044] Table 1 Sample concentration configuration conditions

[0045]

[0046] 4.3) Drug administration: When the cell plating rate in the 6-well plate reaches 50% to 60%, the drug administration is carried out in groups, with 3 replicate wells in each group. 2 mL of culture medium is added to each well of the blank control group and the UV control group, and 2 mL of culture medium containing the sample of the corresponding concentration is added to each well of the sample group. After the drug administration is completed, the 6-well plate is placed in a CO 2 Incubator (37°C, 5% CO 2 ) for 24 h;

[0047] 4.4) UVA irradiation: According to the test groups, all groups except the blank control group were irradiated with UVA at a dose of 30 J / cm 2 After irradiation, place in CO 2 Incubator (37°C, 5% CO 2 ) and continue to culture for 24 h;

[0048] 4.5) ELISA test: After the incubation, the cell culture supernatant was collected in a centrifuge tube, and MMP1 was detected and analyzed according to the operating instructions of the ELISA kit;

[0049] 4.6) Gene expression detection: RNA was extracted and reverse transcribed into cDNA, and then fluorescent quantitative PCR was performed. -△△CT Method to calculate the results;

[0050] 4.7) Calculation of MMP1 inhibition rate: inhibition rate (%) = 100% × (average concentration of MMP1 in UV control group - average concentration of MMP1 in sample group) / average concentration of MMP1 in UV control group. The results are shown in Table 2;

[0051] 4.8) Calculation of the enhancement rate of Collagen III gene expression: enhancement rate (%) = 100% × (sample group gene amplification fold - UV control gene amplification fold) / UV control gene amplification fold. The results are shown in Table 3.

[0052] Table 2 MMP1 inhibition results

[0053]

[0054] The difference was analyzed with the UV control group, P<0.05 indicated a statistical difference, P<0.01 indicated a significant statistical difference, and a significant difference indicated that it had the effect of inhibiting the secretion of MMP1. The King's formula was further used to determine the synergistic effect of the composition, that is, Q=E(a+b) / (Ea+Eb-Ea×Eb), when Q<0.55 was obvious antagonism, when Q was between 0.55 and 0.85 was antagonism, when Q was between 0.85 and 1.15 was additive, and when Q>1.15 was synergistic. Taking Example 1 as an example, Ea=5.34%; Eb=6.83%; E(a+b)=15.65%, substituting into the King's formula to obtain Q=1.33 of Example 1, it is proved that ginsenoside RG2 and type III collagen have the effect of synergistically inhibiting the secretion of MMP1 at 2:1.

[0055] The results in Table 2 show that the composition of the present application can effectively inhibit the secretion of matrix metalloproteinase MMP1, especially when recombinant type III collagen and ginsenoside RG2 are present in an appropriate mass ratio, recombinant type III collagen and ginsenoside RG2 have a synergistic effect of inhibiting the secretion of MMP1.

[0056] Metal matrix proteinase MMP1 is the main cause of skin aging, characterized by sagging or rough skin, and the deepening of skin surface wrinkles and reduced skin elasticity due to collagen degradation. Increasing the expression of MMP-1 will also lead to the decomposition of collagen. Therefore, it can be expected that the composition of the present application can reduce collagen degradation, improve skin wrinkles and increase skin elasticity.

[0057] Table 3 Collagen III gene amplification results

[0058]

[0059] The difference was analyzed with the UV control group. P<0.05 indicated a statistical difference, and P<0.01 indicated a significant statistical difference. A significant difference indicated that it promoted the production of collagen. The COLBY formula (SR Colby, Weeds, Vol. 15, No. 1, pp. 20-22, 1967) was further used to verify whether the sample group to be tested produced a synergistic effect. That is, E = X + Y - XY / 100, when E actual > E, it is synergistic; when E actual < E, it is antagonistic; when E actual = E, it is additive. Taking Example 2 as an example, E = 28.85%, E actual = 48.08%, and E actual > E, which proves that ginsenoside RG2 and recombinant type III collagen have a synergistic effect in promoting collagen production at 20:1.

[0060] From the analysis of the results in Table 3, it can be seen that the composition of the embodiments of the present application can significantly increase the gene expression of type III collagen in fibroblasts, and has the effect of synergistically promoting the gene expression of type III collagen, which indicates that the composition of the present application can effectively promote the production of endogenous type III collagen.

[0061] The above is only the embodiment of the present application, and the protection scope of the present application is not limited by these specific embodiments, but is determined by the claims of the present application. For those skilled in the art, the present application can have various changes and variations. Any modification, equivalent replacement, improvement, etc. made within the technical ideas and principles of the present application should be included in the protection scope of the present application.

Claims

1. A skin care composition, characterized in that It comprises ginsenoside RG2 and type III collagen, wherein the weight ratio of the ginsenoside RG2 to the type III collagen is 1 to 50:

1.

2. The skin care composition according to claim 1, characterized in that The weight ratio of the ginsenoside RG2 to the type III collagen is 1 to 30:1; Preferably, the weight ratio of the ginsenoside RG2 to the type III collagen is 2 to 20:

1.

3. The skin care composition according to claim 1, characterized in that The concentration range of the ginsenoside RG2 is 0.0001% to 1%, and the concentration range of the type III collagen is 0.0001% to 1%.

4. The skin care composition according to claim 3, characterized in that The composition may further include physiologically acceptable excipients or other active ingredients.

5. Use of the skin care composition according to any one of claims 1 to 4 in inhibiting collagen degradation and / or promoting collagen production.

6. The use according to claim 5, wherein the promoting collagen production comprises promoting type III collagen production.

7. Use of the skin care composition according to any one of claims 1 to 4 in preventing and / or alleviating aging.

8. The use according to claim 7, characterized in that: The prevention and / or alleviation of aging includes removing wrinkles and / or increasing skin elasticity.

9. Use of the skin care composition according to any one of claims 1 to 4 in the preparation of external skin products.

10. The use according to claim 9, characterized in that: The skin external products include one or more of skin care products, makeup products, hair products, sunscreen products, and skin external medicines.

Images